Mode
Text Size
Log in / Sign up
Phase 3 Completed N=62 Randomized Triple-blind Treatment

PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate

Healthy
Source: ClinicalTrials.gov NCT01327495 ↗
Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Oct 2017
Primary outcomePrimary: Prostate Tissue DHT Concentrations After Treatment — 4.05; 4.26; 2.99; 3.88 ng/g
◆ Published Evidence
Established
27citations · ~3 / year
Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone.
The Journal of clinical endocrinology and metabolism · 2016 · Open access · High-confidence link

Summary

The investigators will conduct a three-month, randomized, placebo-controlled trial comparing the effects of increasing doses of androgen supplementation with Testosterone (T) gel on the prostate in healthy men who are treated with acyline to block gonadal androgen production.

Linked Publications

  • Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone.
    The Journal of clinical endocrinology and metabolism · 2016 · 27 citations · Open access · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Prostate Tissue DHT Concentrations After Treatment
4.05; 4.26; 2.99; 3.88; 4.12; 5.11
PRIMARY
Serum Testosterone
4.6; 1.9; 3.4; 3.5; 6.1; 7.7
PRIMARY
Dihydrotestosterone (DHT)
0.3; 0.6; 0.9; 1.0; 1.5; 1.8
PRIMARY
Prostate Tissue Testosterone Concentrations After Treatment
0.3; 0.13; 0.125; 0.18; 0.195; 0.3
SECONDARY
Prostate Specific Antigen
0.82; 0.48; 0.61; 0.58; 0.52; 0.76
SECONDARY
Prostate Volume
19; 18; 19; 15; 16; 20
SECONDARY
International Prostate Symptom Score (IPSS)
1; 2; 2.5; 0; 2.5; 4

Eligibility Criteria

Inclusion Criteria

In good health, without severe systemic illness (i.e., renal, liver, cardiac or lung disease, cancer, insulin dependent diabetes)

  • Male between the ages of 25 and 55 years old
  • Able to understand and comply with protocol instructions and requirements
  • International Prostate Symptom Score (IPSS) 320 pounds or BMI > 40
  • PSA Level > 2.1
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01327495) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search